a Post-translational lipid modifications farnesylation and geranylgeranylation of proteins (protein prenylation) have been identified to mediate critical events in cancer, cardiovascular disorders, malaria and bone disorders like osteoporosis. To date eight compounds are commercialized for the treatment of bone disorders, and there are considerable efforts to develop selective small molecules that inhibit protein prenylation. This review summarizes the approaches currently employed to synthesize new inhibitors of isoprenoid biosynthesis. Bisphosphonates are mainly prepared through reaction of carboxylic acids with phosphorus reagents, Michael addition to tetraethylvinylidenebisphosphonate and alkylation of tetralkylmethyl bisphosphonate. Approaches to non-bisphosphonate derivatives include a variety of methodologies depending on the structure of the target compound.
Introduction
Isoprenoids (also known as terpenoids) are considered the most ancient and diverse class of natural products.
1 They have been found in sediments from 2.5 billion years ago 2 and more than 40 .000 representatives have been found in all kingdoms of life.
3 They participate in a great variety of basic biological functions in plants 4, 5 (e.g. growth regulation, pigments) and mammals [6] [7] [8] (e.g. steroids metabolism, cellular signaling, antioxidants), and have been used in the food, pharmaceutical, chemical and biofuel industries.
9,10
Isoprenoids are biosynthesized ubiquitously in eubacteria, archaebacteria and eukaryotes by the consecutive condensation of the ve-carbon monomer isopentenyl diphosphate (IPP) to its isomer dimethylallyl pyrophosphate (DMAPP) (Fig. 1) in mammals and yeast IPP is synthesized in the cytosol and endoplasmic reticulum from acetyl-CoA through mevalonic acid (mevalonate pathway), in higher plants and other microorganisms IPP is synthesized in the plastids by the condensation of pyruvate with glyceraldehyde-3-phosphate through 1-deoxyxylulose-5-phosphate (DXP) -also called methylerythritol (MEP pathway). Two consecutive condensations of IPP and DMAPP catalyzed by farnesyl pyrophosphate synthase (FPPS) provide geranyl diphosphate (GPP) and farnesyl diphosphate (FPP). The former is the precursor of monoterpenes and the latter of sesquiterpenes, triterpenes and sterols (via squalene biosynthesis) as well as other important secondary metabolites like ubiquinones and dolichols. An additional condensation of FPP with IPP, catalyzed by the enzyme geranylgeranyl pyrophosphate synthase (GGPPS), furnishes geranylgeranyl pyrophosphate (GGPP) precursor of diand tetraterpenes and carotenoids (Fig. 1) .
Given the importance of the metabolites accessible from isoprenoid biosynthesis, the enzymes involved in the process are excellent drug targets. 13, 14 The non-mevalonate pathway (MEP pathway) is not present in mammalian systems; consequently the enzymes involved in MEP pathway are attractive drug targets 15 for the development of herbicides, antimicrobial drugs and ghting against pathogenic microorganisms like P. falciparum (malaria), 16, 17 T. cruzi (Chagas disease) 18, 19 and M. tuberculosis. 20 Enzymes in the MEP pathway, IspG and IspH, are anti-infective drug targets 21 and HMG-CoA reductase involved in the synthesis of IPP is the primary target of hypocholesterolemic drug therapy.
22
Protein prenylation, in particular farnesylation and geranylgeranylation, is one of the essential post-translational protein modication in the eukaryote. 23 Therefore inhibition and/or modulation of the enzymes FPPS and GGPPS will affect not only to essential secondary metabolites derived from isoprenoid biosynthesis 24 but also to the functionality of prenylated proteins. 25 agents. 26 In particular, human FPPS is a drug target for cancer, 27, 28 osteoporosis and related diseases,
29-31
Paget's disease, 32,33 metastatic diseases, 34 and cardiovascular disorders. 35 Inhibition of human GGPPS has been reported as a new route to bone antiresorption 36 and the same enzyme from Plasmodium has been identied as a target against malaria.
37
The multiple sequence alignment of FPPS and GGPPS found in different organisms 38, 39 makes that the same potential inhibitor should be tested against both enzymes from diverse biological sources. The main group of inhibitors is constituted by bisphosphonates (BPs), 40 structural analogues of DMAPP considered chemically stable analogues of inorganic pyrophosphate. Bisphosphonates, known from more than 40 years 41 are being used clinically in the treatment of osteoporosis and malignant bone diseases (Fig. 2) .
42
Simple bisphosphonates correspond to analogues of pyrophosphate 1 with therapeutic properties in which the bridging oxygen atom has been replaced by a methylene group that can incorporate non-nitrogenated substituents. Typical examples are etidronate 2 and cloronate 3 and their mechanism of action consists of being incorporated to non-hydrolyzable analogues of ATP, inducing osteoclast apoptosis.
43
On the other hand, nitrogen-containing bisphosphonates (e.g. alendronate 4, pamidronate 5, ibandronate 6, risedronate 7, zoledronate 8) showed to be more than 10 000 times more active than non-nitrogenated derivatives. These analogues have a diverse mechanism of action causing (i) disruption of normal function of essential signaling proteins 44 and (ii) accumulation of IPP which is incorporated into a toxic nucleotide metabolite. 45 More recently, a variety of non-nitrogenated bisphosphonates like tiludronate 9 and others bearing arylsulfonium and phosphonium groups showed cytotoxicity against cancer, inhibition of TpFPPS and stimulation of T-cells in the human immune system revealing that the presence of a nitrogen atom is not strictly necessary. In addition to bisphosphonates, other inhibitors including quinoline and salicylic acid derivatives, have been reported. These non-bisphosphonate inhibitors bind to an allosteric site on FPPS identied by X-ray crystallography.
46
The goal of this review is to highlight synthetic methodologies directed to the preparation of FPPS and GPPS inhibitors. Several reviews have been reported elsewhere on the design of inhibitors of isoprenoid synthase enzymes 13, 14, 47 and their mechanism of action. 45, [48] [49] [50] [51] The reader is directed to consult those reviews for details on therapeutic effects. Since the main focus of this survey is discussion on chemical approaches, references to biological activities of the inhibitors is only shortly reviewed here. No patents are considered in this review since they have been recently surveyed. 52, 53 The review is organized on the basis of the structure of the inhibitor, i.e. bisphosphonates and non-bisphosphonates and then by the synthetic methodologies employed for their synthesis.
Bisphosphonates

Reaction of carboxylic acids with phosphorous reagents
The most general and attractive approach for preparing 1,1-bisphosphonates is the reaction of a carboxylic acid, easily accessible by conventional methods, with an inexpensive phosphorous reagent like phosphorous trichloride. Due to high therapeutic interest of 1,1-bisphosphonates, the rst reports regarding their synthesis were published as patents and no clear experimental details were given, the reaction being difficult to scale up and lacking of reproducibility. Indeed, no mechanism of the reaction had been determined and a great variability was observed in reactants ratio, temperature, reaction time and work-up. In 1995, Kieczykowski and Jobson, from Merck and Co., Inc., reported a general procedure for reacting a carboxylic acid with phosphorous acid and phosphorous trichloride in the presence of methanesulfonic acid (Scheme 1).
54
Since then, this method has been the most widely used for the synthesis of 1-hydroxy-1,1-bisphosphonates although in some particular case it has been reported contamination of the product with the methanesulfonate salt, that can be avoided by performing the reaction without solvent. 55 The procedure is amenable of being used with several substrates including those bearing an amino functionality. 36, 56 For instance, alendronate 4 and pamidronate 5, have been prepared by this route 57 and served as precursors of substituted analogues like compounds 13 (Scheme 2). 58, 59 Similarly, conjugates 14 have been prepared by condensation of 5 with the corresponding carboxylic acid.
60
Other conjugates include incorporation to nucleosides 61 and oligonucleotides. 62 Pamidronate 5 prepared by this route has been further employed for the synthesis of 211 At-labeled amidobisphosphonates.
63
Alendronate 4 can also be obtained in a straightforward manner from pyrrolidone (Scheme 3). 64 Hydrolysis of 15 in aqueous methanesulfonic acid followed by reaction with phosphorous trichloride and hydrolysis with water furnished compound 4. Good yields in the synthesis of heterocyclic (risedronate 7, zoledronate 8) and aminoalkyl bisphosphonates were obtained in just 20 min using microwaves and sulpholene as a solvent in the rst stage of the reaction (Scheme 4). 65 A chiral analogue of risedronate 7 was prepared starting from 3-benzyloxybenzaldehyde 18 which was transformed into carboxylic acid 22. Reaction of 22 with phosphorous acid and phosphorous chloride afforded analogue 23 (Scheme 5). 66 The complex formed from HsFPPS and racemic 23 revealed that only Risomer was present in the active site revealing a high enantiospecicity of the enzyme.
Oldeld and co-workers have demonstrated that the methodology originally reported by Kieczykowski and Jobson 54 allows preparing a huge number of different compounds, including aromatic, aliphatic, sulfur-containing and nitrogen-containing heterocyclic derivatives. [67] [68] [69] [70] [71] The exact protocol involved a hydrolysis, aer the reaction of the carboxylic acid with phosphorous acid and phosphorous trichloride, and pH adjustment to 4.3 with a 50% NaOH solution, followed by recrystallization from water.
67
A modied procedure was reported by the same group for the synthesis of pyridinium-1-yl bisphosphonates 27. The corresponding carboxylic acids 26 prepared through a cross-coupling reaction followed by N-alkylation with bromoacetic acid, were made to react with 5 equiv. of phosphorous acid and 5 equiv. of phosphorous trichloride in toluene without methanesulphonic acid. Aer treating the mixture with 6 N HCl and reux for 1 h, addition of 2-propanol precipitated the 1,1-bisphosphonates which were further recrystallized from ethanol/water (Scheme 6). This protocol was also applied to the synthesis of aliphatic and aromatic derivatives with or without heteroatoms, demonstrating a great tolerance with respect to the chemical nature of the substrates. 73 Labelled pamidronic acid- 13 Pyridinium uorescently-labeled conjugates of risedronate 7 were synthesized using an epoxide linker which was bonded to the pyridyl nitrogen. The conjugates were used for uorescence imaging of Bacillus subtilis.
75
Despite this synthetic activity that demonstrate the utility of the carboxylic acid-approach, various inconsistent procedures appeared in patents concerning the synthesis of the most clinically used zoledronic and risedronic acids which has been the matter of some controversy regarding the reagents and the ratio between them to be used. Dedicated reviews have been reported with the aim of clarifying the situation including the mechanism 76 of the reaction. 77, 78 In 2011, Keglevich and co-workers nally established that the best conditions correspond to the use phosphorous trichloride in 1 : 3.2 molar ratio in methanesulfonic acid. 79 Alternatively, it has also been reported the use of benzenesulfonic acid as a solvent. 80 When the reaction is carried out in the presence of paraformaldehyde, bisphosphonic acids can be obtained without the addition of water, 81 the use of microwaves enhancing the yield of the reaction.
82,83 By using their conditions, Keglevich and co-workers reported the synthesis of etidronate 2, alendronate 4, pamidronate 5, ibandronate 6, risedronate and 7 zoledronate acid 8 (Scheme 7). 84 The exact treatment of the reaction comprised the use of only 3.2 eq. of phosphorous trichloride as the P-reagent in methanesulfonic acid as a solvent (without addition of phosphorous acid). In fact, it had been reported the use of that solvent for large-scale preparations. 85 Time and temperature were adjusted in each case for the rst stage of the reaction at which time water was added and the resulting mixture was heated at 105 C for 5 h. This was followed by hydrolysis with 10 N NaOH and pH adjustment to 1.8-2.0. Notably, the different dronic acids prepared required different purication conditions. Whereas 2, 4 and 6 were puried by direct precipitation in water, 5 was puried by digestion in MeOH followed by precipitation in water, 7 was puried by washing with water and 8 was puried by recrystallization from HCl. Further work in different solvents 86 allowed establishing the best conditions for doing the reaction.
83
A variation using phosphorous oxychloride has allowed a one-pot multigram synthesis of zoledronic acid 8 in high yield (Scheme 8). 87 The procedure has been carried out with 200 g of compound 28, easy accessible from imidazole. 88 The use of phosphorous oxychloride has also been successfully used for the synthesis of aledronate 4 and risedronic acid 7. 89 On the other hand, phosphorous trichloride was the preferred reagent in the synthesis of benzidronate.
90
Nitriles 29 can also be used as an alternative to carboxylic acids and the reaction can be performed under similar conditions 99 Tc by forming the corresponding complex.
Reaction of acylphosphonates with dialkyl phosphites
In some instances, the direct reaction between a carboxylic acid and phosphorus trichloride takes place with low yields or fails completely as in the case of sterically hindered a-aminoacids. A discussion comparing this route with that developed at the Merck company has been reported. 93 An alternative is the use of the acyl chloride as starting material. The Arbuzov-type reaction 94 with a di-, trialkyl phosphite provides an a-ketophosphonate (acylphosphonates) capable of reacting with another molecule of di-, trialkyl phosphite to give the corresponding 1-hydroxy-1,1-bisphosphonate. The rst report on this approach 
97
Acrylic ester bisphosphonates 35,36 with numerous potential applications in biomedicine are also accessible through this approach.
98
The direct use of trialkyl phosphites is also possible. A series of a-amino acid derived bisphosphonates 42 has been prepared in good yield by using as starting materials N-phthalimidoprotected amino acids and using sequentially tri-and diethyl phosphite as P-reagents (Scheme 11).
99 Although the addition of phosphites is consecutive, the reaction is carried out in a onepot procedure without isolating the intermediate ketophosphonate 40.
Final deprotection of the amino group was made with 6 N HCl. The use of hydrazine is also possible and better yields are obtained. By using this variation, alendronate 4, pamidronate 5, and neridronate have been prepared as mono-and diesters, which were soluble in water at physiological pH. 100 The use of tri-and dimethylphosphite led to shorter reaction times. Conjugation of a uorophore to methyester-protected pamidronate 45, prepared from b-aminoacid 12, was performed in DMSO in the presence of N-methylmorpholine (Scheme 12). Compound 48 was used as a contrast agent in image-guided surgery of large animals.
101
The use of dimethylphosphite also afforded better results in the synthesis of alendronate 4 reported by Seki in which both P- reagents were compared. Differences were found in the nal hydrolysis of the phosphate esters. Ethyl esters showed a lower reactivity towards hydrolysis (Scheme 13).
102
Analogues of alendronic acid 4 have been prepared from the common precursor 53 through a practical one-pot, three step methodology. The protection of the 1-hydroxy group was necessary for avoiding mixtures in the acylation step (Scheme 14).
103
A series of bisphosphonates bearing either the nitrogencontaining NO-donor furoxan (1,2,5-oxadiazole 2-oxide) or the related furazan (1,2,5-oxadiazole) systems in the lateral chain has been prepared by using trimethylphosphite as P-reagent (Scheme 15).
104
Activation of the carboxylic acid as a dioxaborolane can be an alternative to the acid chloride. This approach requires the use of tris(trimethylsilyl)phosphite since dialkylphosphites showed no reaction (Scheme 16).
105 Also in this case a poor reactivity was observed for N-hydroxysuccinimide esters towards methyl or phenyl bis(trimethylsilyl)phosphites, in good agreement with previously reported results. The reaction, carried out in the absence of solvent and under activation with microwaves takes place in several minutes with good yields. 109 In all these cases the bisphosphonates prepared by this route lack the 1-hydroxyl group but consist of interesting structurally constrained analogues.
100
Michael addition to tetraethylvinylidenebisphosphonate
Alkylation of tetralkylmethyl bisphosphonate
Alkylation of tetraethyl bisphosphonate 79 is an expeditious way of preparing bisphosphonates lacking the 1-hydroxy groups. However, precise reaction conditions must be used in order to avoid elimination reactions.
110 Alkylation of 79 with farnesyl and geranyl bromides 80 and 81 using sodium hydride as a base provided bisphosphonates 82a,b. Further hydrolysis furnished free bisphosphonates 83a,b (Scheme 21).
On the other hand, using potassium hydride an undesired elimination reaction was observed.
110 By oxidizing the allylic position of the terminal trisubstituted double bond in 80, it was possible to introduce additional substituents at the end of the isoprenoid unit. 112 Further alkylation of compound 80 furnished, aer hydrolysis, uorescent anthranilate analogue 85 that showed some inhibition in geranylgeranylation.
113
Aminobisphosphonate 86 was alkylated, aer protection of the amino group, with methyl 2-bromo acetate. Potassium carbonate in the presence of triethylammonium bromide was used for deprotonating 86. Further deprotection yielded the target bisphosphonate (Scheme 22). The presence of a hydroxamate moiety induces a major attitude in terms of metal chelation.
117 Thus, the hydroxamic group is expected to improve the ionic and/or metal chelation interactions with the active site of FPT (Farnesyl Protein Transferase).
The synthesis of N-methyl substituted hydroxamic acid 103 was carried out starting from N-methyl-O-benzyl-hydroxylamine hydrochloride 94 and aspartic acid derivative 95 (Scheme 25).
118
Deprotection of 96 and successive coupling of resulting 97 with tripeptide H-Val-Leu-Ser-OMe 98 furnished tetrapeptide 99.
Basic hydrolysis with NaOH of the ester group in 99 provided 100 with 20% of the free aspartic acid derivative resulting from cleavage of hydroxamic function. The use of sodium carbonate in 2 : 1 MeOH-water avoided the formation of byproducts maintaining unchanged the chirality. Further deprotection steps gave provided 103 in good yields. In the same work, the authors prepared hydroxamic bisubstrate analogs 114, 116, 118 and 120 by introducing a full farnesyl group on the hydroxamic portion to improve the inhibition of FPT (Scheme 26).
The synthesis was carried out by a multistep sequence utilizing farnesyl bromide 104 as starting material which was transformed into 105 in moderate yield. Acylation of 105 required 2 eq. of the 3-carbomethoxy-propionyl chloride and 3 eq. of DIPEA. Saponication of the resulting 107 furnished intermediate 108 which was coupled with various tripeptides to give bisubstrates 114, 116, 118 and 120 aer opportune removal of protective groups. A critical step in the synthesis was the deprotection of THP group in the presence of farnesyl chain. The problem was solved by using p-TsOH although the yields were modest.
In 1993, the chaetomellic acids A and B 121 and 122, classied as alkyl cis-dicarboxylates, were discovered to be potent inhibitors of FPTase because of analogy with the active site of FPP (Fig. 3) .
119,120
Singh and collaborators carried out the synthesis of various chaetomellic acids derivatives through a sequence of three steps. 121, 122 Starting from fatty acid esters 123-125, the reaction with methylpyruvate in the presence of LDA at À78
C furnished a 1 : 1 diastereomeric mixture of aldol products 126 and 127 (Scheme 27).
A b-elimination reaction of aldol substrates -opportunely protected with a tosyl group produced the tetra-substituted olens 130-132 via anti or syn periplanar elimination. In the nal step, the hydrolysis of ester derivatives by reuxing with a NaOH solution gave chaetomellic acid analogs 133-135 in moderate yield. Tucker et al. showed that a large arylthio or aryloxy group adjacent to the cyano function provided compounds with high activity against GGPP and FPT enzymes.
123,124
An approach to the synthesis of inhibitors 139-155 was developed by initial reductive amination of aldehydes 136 with N-Boc-piperazine, titanium iso-propoxide and NaBH 3 CN in THF-EtOH (Scheme 28).
The resulting compounds 137 were deprotected by TFA furnishing the free amines 138 in good yields. The reaction of 138 with appropriate p-nitrophenyl carbonate yielded target compounds 139-155 in good yields.
Phosphonocarboxylate (PC), analogues of N-BP, characterized by a carboxylic and a phosphonic group on the same carbon, exhibit a chiral structure in contrast to the respective bisphosphonates, increasing the possibility of stereospecicity in their biological activity.
125-128
Minodronic acid 156 (Fig. 4) was the rst bisphosphonate developed and approved for osteoporosis treatment in Japan and today is available in a number of countries worldwide.
McKenna and co-workers reported, in 2010, the synthesis of the analogue 157 starting from imidazo[1,2-a]pyridine 158 (Scheme 29).
129 A Vilsmeier-Haack formylation of 158 furnished aldehyde 159 which was transformed into 160 and then the dehydroaminoester 162. Hydrolysis of 162 and further addition of diethyl phosphite to the resulting 163 furnished protected bisphosphonate 164 that was conveniently deprotected into 156. Resolution of 156 enantiomers by chiral HPLC furnished the (+)-156 isomer, which revealed a potent inhibitory activity of RGGT.
Replacement of the geminal hydroxyl moiety of PC with a halogen atom allowed to obtaining three a-halo derivatives 172-174 with potential biological activity against RGGT. 130 The choice of this substitution had a signicant impact to studying the role of the heterocyclic base respect to inhibition of enzyme activity. Starting from 159, a multi-step approach was carried out to synthesize common precursor 167. Halogenation with Selectuor, N-chlorosuccinimide or N-bromosuccinimide provided haloderivatives 169-171. Further hydrolysis of the ester groups afforded the free acids 172-174 (Scheme 30).
Phosphonocarboxylates can also be approached by routes commonly used for preparing bisphosphonates such as Arbuzov-Michaelis reaction of trialkyl phosphite with a-bromoesters, 131 reaction of diethyl phosphite with a-ketoesters, 129 and reaction of enolates and chlorodialkyl phosphites. 132 In addition, the insertion of carboxylic function can be performed by using lithium alkylphosphonate and diethyl carbonate 133 or CO 2 .
134 Another methods include alkylation of trialkyl phosphonoacetate 135 and functionalization of trialkyl 2-phosphonoacrylate via Michael-type addition.
136
Recently, Coxon and colleagues used various approaches among those described to synthesize phosphonocarboxylates 175-178 showing some structural diversity (Fig. 5) . The synthesis of 187 proceeded from 182. Coupling with cyclopropyl cyanocuprate 183 gave 184 in 71% yield. Reduction of the ester group with DIBALH produced the corresponding alcohol 185 that was chlorinated and immediately treated with tris(tetrabutyl ammonium) hydrogen diphosphate to give 187 (Scheme 32).
Similarly, the synthesis of 193 was carried out through an initial reaction between 182 and the t-butyl cyanocuprate 188. Further steps of reduction, chlorination and pyrophosphorylation furnished 191 (Scheme 33).
Gibbs and co-workers developed a stereoselective synthesis of cis-isoprenoid analogues such as 199 using the vinyl triate method (Scheme 34). 139, 140 The fundamental step was the stereoselective preparation of triate derivative 196 from the enolate of b-ketoester 194. The choice of solvent was found to have a signicant impact on the trend of the reaction, not only in terms of yield, but also in the stereoselectivity. In fact, the use of DME instead of THF resulted in a loss of stereocontrol, while DMF as reaction solvent promoted only the stereoisomer The presence of a sulfur atom as thiodiphosphate seems to promote the (S)-alkyl thiodiphosphates regioselectivity. Therefore, (S)-alkyl isopentenyl and allylic thiodiphosphates 204 and 206-209 were obtained by the procedure illustrated in Scheme 36.
142 The reaction proceeded through slow addition of the isoprenoid derivatives 203 and 205a-d to an acetonitrile solution containing tris(tetra-n-butylammonium) thio-pyrophosphate (SPP i ). The residue was passed through an ion-exchange column, replacing the tetra-n-butylammonium cation with ammonium in order to purify the nal product by cellulose chromatography (57-89% yield).
Quinolines and salicylic derivatives have also been shown to be inhibitors of FFPS. In particular, the combination of quinolines with zoledronate seems to amplify the inhibition effect respect to the individual inhibitor. Therefore, a series of quinoline derivatives was synthesized starting from aniline 210 and ethyl 4-chloroacetoacetate 211 in PPA at 130 C (Scheme 37). Compound 220 represented the starting point to synthesize a variety of salicylic acid analogues through an initial reaction with boronic acid by microwave irradiation. The nal step with LiOH in MeOH/THF was promoted by the use of microwaves yielding substrates 221 (Scheme 38).
The same authors prepared a variety quinoline substrates 222-228 via different synthetic strategies (Fig. 6) .
In particular, a unique method allowed the simultaneous synthesis of three active quinoline compounds 226-228 starting from nitration of 8-bromoquinoline-2(1H)-one 229 (Scheme 39).
Suzuki coupling of the crude of the nitro-derivatives 230 with naphthyl boronate gave 231 that was converted in 232 with POCl 3 in the presence of N,N-dimethylaniline and Et 4 NCl. Palladium-catalyzed carbonylation and reduction of nitro group of 232 produced the intermediate esters 233-235 in moderate yield that were hydrolyzed with LiOH to perform quinolines 226-228. 
Concluding remarks
Historically, bisphosphonates are benchmark drugs for the treatment of a variety of bone disorders including osteoporosis and bone metastasis. Their inhibitory activity of the isoprenoid biosynthesis resulted in other important applications as modulators of the metabolism of several protozoa parasites thus also being potential therapeutic agents for the treatment of trypanosomiasis (Chagas disease), leishmaniasis, toxoplasmosis and malaria. Bisphosphonates could also be useful in the treatment of other diseases such as breast cancer, myeloma multiple and progeria. Both clinical success in bone disorders and expectative for other diseases prompted the enormous synthetic activity directed to the preparation of bisphosphonates and more recently, nitrogen-containing bisphosphonates which are demonstrated better biological properties. In general, the reaction of carboxylic acids with phosphorous reagents like POCl 3 is the preferred approach to bisphophonates. The reaction, however, is very sensitive to steric hindrance and in such cases an Arbuzov-type reaction results more advisable. More recently, the use of tetraethylvinylidenebisphosphonate as the source of phosphorylated part of the molecule has facilitated enormously the access to a variety of bisphophonates. Moreover, the use of such a reagent presented a high tolerance to a variety of functional groups. For the particular case of bisphosphonates lacking the hydroxyl group the alkylation of tetralkylmethyl bisphosphonate is preferred; however, elimination reactions are common undesired lateral processes that, on the other hand, can be eliminated by using precise reaction conditions. The presence of two phosphate units, in addition to difficult manipulation and purication, limits the oral bioavailability and contribute to undesired side-effects. In this respect, novel bisphosphonate analogues that selectively target FPPS and GGPPS enzymes might provide notable advantages over the currently used drugs and this is now the subject of intense investigation in medicinal chemistry and chemical biology. Achieving this target implies to have at disposition a series of synthetic strategies that allow not only the preparation of the target compound but also structural variations of the parent compound that provide lead compounds for further studies for treatment of the several diseases related to isoprenoid biosynthesis.
